A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.

Kuei-Ting ChenRussell W MadisonJay MooreDexter JinZoe FleischmannJustin NewbergAlexa SchrockNeeru BhardwajKatherine T LofgrenJie HeGarrett FramptonPriti HegdeDavid FabrizioMichael J PishvaianEricka EbotAatur SinghiEthan Sokol

Published in: The oncologist (2023)

A scar-based HRD biomarker was identified in a significant fraction of PC patients and is predictive of FOLFIRINOX benefit. Incorporating a biomarker like HRDsig could identify the right patients for platinum chemotherapy and potentially reduce FOLFIRINOX use by over 40%, minimizing toxicities with similar survival outcomes. Confirmatory studies should be performed.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
locally advanced
small cell lung cancer
peritoneal dialysis
prognostic factors
patient reported